Introduction {#s1}
============

The spread of multidrug-resistant (MDR) *Acinetobacter* strains among critically ill, hospitalized patients, and subsequent epidemics, have become an increasing cause for concern [@pone.0065026-Dijkshoorn1], [@pone.0065026-Peleg1]. These organisms are one of the most common causes of infection in patients in the intensive care unit (ICU) and are associated with a greater risk of hospital death by causing catheter-related infection, pneumonia, urinary tract infection, wound infection, and primary bacteremia in patients with critical illness [@pone.0065026-Vincent1]--[@pone.0065026-Shields1]. The organisms' ability to accumulate diverse mechanisms of resistance limits therapeutic agents and makes the infection difficult to treat [@pone.0065026-Cai1].

To date, more than 30 *Acinetobacter* species have been described [@pone.0065026-Nemec1]. Among these, *Acinetobacter baumannii* (genotype 2) is the most commonly found in clinical specimens. However, recently, infection caused by other *Acinetobacter* species belonging to the *A. calcoaceticus-A. baumannii* (ACB) complex, including *A. nosocomialis* (known also as 13 TU), *A. calcoaceticus* (genotype 1), *A. pittii* (genotype 3), and *Acinetobacter* genomic species "close to 13 TU", has caused concern [@pone.0065026-Nemec2], [@pone.0065026-Sahl1]. Although these are increasingly reported as human pathogens with the introduction of genotyping, it is impossible to distinguish these from *A. baumannii* by automation systems or phenotypic tests [@pone.0065026-Nemec2], [@pone.0065026-GernerSmidt1].

For these reasons, it is important to know whether or not the clinical features, risk factors, and outcomes differ according to species. To date, few studies have been published that evaluate this matter using genotypic assays in patients with *Acinetobacter* bacteremia [@pone.0065026-Chuang1]--[@pone.0065026-Wisplinghoff1]; however, among these reports, the influence of genospecies on outcome is inconsistent. Thus, we compared the clinical features, antimicrobial resistance, and outcome of bacteremia caused by *A. baumannii versus* non-*baumannii* ACB complex strains.

Patients and Methods {#s2}
====================

Ethics {#s2a}
------

This study was approved by the Institutional Review Board of Chonnam National University Hospital. A waiver of consent was granted given the retrospective nature of the project.

Patients {#s2b}
--------

All adult patients (age, ≥16 years) with bacteremia caused by ACB complex who were admitted to Chonnam National University Hospital (1000 beds; Gwang-ju, Republic of Korea) from January 2003 to December 2010 were included. Only patients with their first episode of *Acinetobacter* bacteremia were included.

Data Collection {#s2c}
---------------

Demographic and clinical data were collected by reviewing the electronic medical records of the patients and included comorbid conditions, duration of ICU and hospital stay, use of a ventilator, and use of central venous catheters at the time of bacteremia onset. The severity of patient infection was evaluated using Acute Physiology and Chronic Health Evaluation (APACHE) II scores within 24 h of bacteremia onset.

Microbiological Tests {#s2d}
---------------------

*Acinetobacter* was identified using the automated system Vitek 2 (bioMérieux, Marcy l'Etoile, France). *Acinetobacter* species were determined on the basis of partial *rpoB* gene sequences (468 bp) detected using the primers Ac1055F (GTGATAARATGGCBGGTCGT) and Ac1598R (CGBGCRTGCATYTTGTCRT), as described by us previously [@pone.0065026-Ko1], [@pone.0065026-Park1]. *In vitro* susceptibility testing was conducted using Vitek 2 (bioMérieux).

Definitions {#s2e}
-----------

Multidrug resistance (MDR) was defined if an isolate showed resistance to more than one of the following five antimicrobial agents: imipenem, ciprofloxacin, amikacin, cefepime, and piperacillin/tazobactam, in accordance with Paterson's suggestion [@pone.0065026-Paterson1]. Appropriate empirical antibiotics was defined as the use of at least one antibiotic to which the *Acinetobacter* strain was susceptible within 48 days from the onset of bacteremia. Mortality was defined as *Acinetobacter*-related in the absence of another definite cause of death [@pone.0065026-Jang1].

Statistical Analysis {#s2f}
--------------------

Categorical variables were compared using Fisher's exact test or the Pearson χ2 test, and continuous variables were compared using Student's *t*-test or Mann-Whitney rank sum test, as appropriate. Variables with *P* values ≤0.10 in the univariate analysis were included in the multivariate analysis. Multivariate analyses were performed using a logistic regression model in the backward stepwise conditional manner. All tests of significance were two-tailed, and *P* values ≤0.05 were deemed to indicate statistical significance. Statistical analyses of the data were performed using SPSS software (version 19.0; SPSS Inc., Chicago, IL, USA).

Results {#s3}
=======

Study Population and Genospecies Distribution {#s3a}
---------------------------------------------

During the study period, we identified 180 isolates of the ACB complex, including 90 (50%) *A. baumannii*, 60 (33%) *A. nosocomialis*, 17 (9%) *Acinetobacter* genomic species "close to 13 TU", 11 (6%) *A. pittii*, and two (1%) *A. calcoaceticus.*

Comparison of the Clinical Features of Bacteremia Caused by *A. baumannii versus* Non-baumannii ACB Complex {#s3b}
-----------------------------------------------------------------------------------------------------------

The clinical features of bacteremia caused by *A. baumannii* (n = 90) and non-*baumannii* ACB complex (n = 90) bacteria are shown in [Table 1](#pone-0065026-t001){ref-type="table"}. Demographic data were not different between the two groups. ICU onset, mechanical ventilation, and underlying chronic liver disease were risk factors for *A. baumannii* bacteremia, compared to non-*baumannii Acinetobacter* bacteremia (*P*\<0.05). Pneumonia, MDR, and carbapenem resistance were more commonly found in *A. baumannii* bacteremia, while primary bacteremia was more commonly caused by non-*baumannii Acinetobacter* (*P*\<0.05). No significant difference in clinical features was observed between bacteremia caused by *A. nosocomialis*, *Acinetobacter* species "close to 13 TU", and *A. pittii* (data not shown).

10.1371/journal.pone.0065026.t001

###### Comparison of the clinical features of bacteremia caused by *A. baumannii* (n = 90) or non-*baumannii* ACB complex (n = 90).

![](pone.0065026.t001){#pone-0065026-t001-1}

  Variables                                                               No. (%) of patients with bacteremia caused by   *P* value   
  ---------------------------------------------------------------------- ----------------------------------------------- ------------ ---------
  Demographic data                                                                                                                    
  Age^a^                                                                                      60±17                         58±18       0.46
  Male gender                                                                                62 (69)                       53 (59)      0.16
  Underlying illness                                                                                                                  
  Ischemic heart disease                                                                     25 (28)                       16 (18)      0.11
  Trauma                                                                                     13 (14)                       16 (18)      0.54
  Diabetes mellitus                                                                          11 (12)                       14 (16)      0.52
  Cancer                                                                                      8 (9)                        12 (13)      0.34
  Cerebrovascular accident                                                                    7 (8)                         8 (9)       0.79
  Chronic liver disease                                                                      14 (16)                        3 (3)       0.01
  End-stage renal disease                                                                     4 (4)                         4 (4)      \>0.99
  Benign biliary disease                                                                      7 (8)                         7 (8)      \>0.99
  Primary site of infection                                                                                                           
  Vascular catheter                                                                          27 (30)                       27 (30)     \>0.99
  Pneumonia                                                                                  29 (32)                       16 (18)      0.03
  Primary bacteremia                                                                          8 (9)                        18 (20)      0.03
  Intra-abdominal                                                                            12 (13)                        9 (10)      0.49
  Urinary tract                                                                               3 (3)                         7 (8)       0.33
  Soft tissue or wound                                                                        7 (8)                         7 (8)      \>0.99
  Other characteristics                                                                                                               
  Length of hospitalization (day)^b,^ [c](#nt103){ref-type="table-fn"}                     12 (7, 21)                     11 (7, 22)    0.90
  ICU stay at culture                                                                        77 (86)                       57 (63)      0.001
  Mechanical ventilation                                                                     64 (71)                       44 (49)      0.002
  MDR                                                                                        69 (77)                       29 (32)     \<0.001
  Carbapenem-resistance                                                                      51 (57)                       12 (16)     \<0.001
  APACHE II score^a^                                                                          18±7                           17±8       0.30
  Outcomes                                                                                                                            
  30-day mortality                                                                           35 (39)                       14 (16)     \<0.001
  Acinetobacter-related mortality                                                            33 (37)                       11 (12)     \<0.001

ACB, *A. calcoaceticus-A. baumannii*; ICU, intensive care unit; MDR, multidrug resistance; APACHE, acute physiology and chronic health evaluation.

Continuous variables were expressed as means ± SDs ^a^ or medians (IQRs)^b^ and were compared by the Student's *t* test^a^ or Mann-Whitney U test^b^.

Until the onset of *Acinetobacter* bacteremia.

Risk Factors for 30-day Mortality in Patients with *Acinetobacter* Bacteremia {#s3c}
-----------------------------------------------------------------------------

Risk factors for 30-day mortality in the 180 patients with *Acinetobacter* bacteremia are shown in [Table 2](#pone-0065026-t002){ref-type="table"}. In the univariate analysis, *A. baumannii* genospecies, age, pneumonia, MDR, carbapenem resistance, inappropriate empirical antibiotics, and APACHE II score were each associated with 30-day mortality (*P*\<0.05). Multivariate analysis included the following variables: *A. baumannii* genospecies, APACHE II score, age, pneumonia, vascular catheter infection, inappropriate empirical antibiotics, MDR and carbapenem resistance. The independent risk factors for 30-day mortality identified in the multivariate logistic regression analysis included *A. baumannii* genospecies (OR, 3.60; 95% CI, 1.56--8.33), pneumonia, age, and APACHE II score ([Table 2](#pone-0065026-t002){ref-type="table"}).

10.1371/journal.pone.0065026.t002

###### Risk factors for 30-day mortality in 180 patients with *Acinetobacter* bacteremia.

![](pone.0065026.t002){#pone-0065026-t002-2}

  Variables                                          Univariate analysis   Multivariate analysis                                
  ------------------------------------------------- --------------------- ----------------------- --------- ------------------- ---------
  Age[a](#nt105){ref-type="table-fn"}                       55±18                  69±12           \<0.001   1.07 (1.03--1.10)   \<0.001
  Vascular catheter infection                              44 (34)                10 (20)           0.086                       
  Pneumonia                                                23 (18)                22 (45)          \<0.001   2.72 (1.16--6.37)    0.021
  APACHE II score[a](#nt105){ref-type="table-fn"}           16±7                   22±7            \<0.001   1.12 (1.06--1.19)   \<0.001
  MDR                                                      62 (47)                36 (74)           0.002                       
  Carbapenem resistance                                    38 (29)                27 (55)           0.001                       
  Inappropriate empirical antibiotics                      65 (50)                37 (76)           0.002                       
  *A. baumannii* genospecies                               55 (42)                35 (71)          \<0.001   3.60 (1.56--8.33)    0.003

APACHE, acute physiology and chronic health evaluation; MDR, multidrug resistance.

Continuous variables were expressed as means ± SDs and were compared by the Student's *t* test.

The Kaplan-Meier survival curves for *Acinetobacter* bacteremia caused by *A. baumannii* and non-*baumannii* ACB complex strains are shown in [Figure 1](#pone-0065026-g001){ref-type="fig"}. The 30-day survival rate was 84% (72/90) in patients with non-*baumannii* ACB complex bacteremia compared to 61% (55/90) in those with *A. baumannii* bacteremia (log-rank test; *P*\<0.001). No significant difference in survival was identified between patients with *A. nosocomialis* bacteremia (83%; 50/60), *Acinetobacter* species "close to 13 TU" bacteremia (88%; 15/17), and *A. pittii* bacteremia (91%; 10/11).

![Kaplan-Meier curves of survival in 90 patients with *A. baumannii* bacteremia and 90 patients with non-*baumannii* ACB complex bacteremia.](pone.0065026.g001){#pone-0065026-g001}

Discussion {#s4}
==========

In this study, we found that genospecies *A. baumannii* was independently associated with poor outcome in patients with ACB complex bacteremia.

Non-*baumannii* ACB complex are increasingly reported as a cause of bacteremia because of the introduction of genospecies identification. Recent studies showed that *A. nosocomialis* and *A. pittii* comprised 27% and 9% of ACB complex bacteremia in Taiwan [@pone.0065026-Lee1] and 21% and 8% in the USA [@pone.0065026-Wisplinghoff1], respectively, which is less prevalent than *A. baumannii*. However, *A. nosocomialis* and *A. pittii* were sevenfold more prevalent causes of bacteremia than *A. baumannii* in Norway [@pone.0065026-Karah1]. In our study, the proportion of non-*baumannii* species was 50%, and *Acinetobacter* genomic species "close to 13 TU", newly defined as a member of the ACB complex [@pone.0065026-Nemec2], comprised a higher proportion, in contrast to previous reports. This finding suggests that the distribution of prevalent genospecies differs geographically.

Previous studies reported the differences in clinical features between *A. baumannii* bacteremia and non-*baumannii* ACB complex bacteremia [@pone.0065026-Chuang1]--[@pone.0065026-Wisplinghoff1]. ICU onset, mechanical ventilation, higher Pitt bacteremia scores, and chronic obstructive pulmonary disease were factors associated with *A. baumannii* bacteremia, compared to non-*baumannii* ACB complex bacteremia in those studies. MDR, carbapenem resistance, and pneumonia were more commonly found in *A. baumannii* bacteremia, while primary bacteremia itself was more commonly caused by non-*baumannii* ACB complex bacteria. Similar results were found in our study. MDR was more commonly found in *A. baumannii* than non-*baumannii* ACB complex blood isolates, in agreement with our previous studies [@pone.0065026-Ko1]. Additionally, we found chronic liver disease, which is prevalent in Korea, as another risk factor for *A. baumannii* bacteremia.

The relationship between genospecies and outcome of *Acinetobacter* bacteremia was evaluated in some studies; however, the results are inconsistent. In previous studies, which did not identify ACB complex bacteria to the species level with genotyping assays and did not include genotype as a confounding factor in analysis, carbapenem resistance was revealed as an independent risk factor for mortality in ACB complex bacteremia [@pone.0065026-Kwon1]. However, Chuang *et al*. reported that *A. baumannii* species, and not carbapenem resistance, was an independent predictor of mortality in ICU patients with *Acinetobacter* bacteremia in Taiwan [@pone.0065026-Chuang1]. However, another study performed at the same hospital during a similar period reported that bacteremia due to MDR strains, but not *A.* *baumannii per se*, appeared to be associated with a poor outcome [@pone.0065026-Lee1].

In the current study, we also found that *A. baumannii* species, rather than antibiotic resistance, mainly affected mortality, in accordance with a previous [@pone.0065026-Chuang1] and a more recent study performed in the USA [@pone.0065026-Wisplinghoff1]. Recently, Peleg *et al*. suggested that *in vitro* and *in vivo* virulence characteristics differed among individual strains of the ACB complex [@pone.0065026-Peleg2], which provides further evidence of the impact of genospecies on the outcome of *Acinetobacter* bacteremia. Our data also suggest that genotype might be a more significant predictive factor for mortality than carbapenem resistance and that genospecies should be included as a confounding factor in any analysis of risk factors for mortality in patients with *Acinetobacter* infections, because genospecies is significantly associated with MDR and carbapenem resistance [@pone.0065026-Houang1], [@pone.0065026-Lim1] and can affect the outcome. Moreover, our data provide more evidence of the importance of correct genospecies identification, which can predict the outcome of *Acinetobacter* bacteremia.

Our study had several limitations. First, since it was retrospective in design, the factors influencing the physicians' choice of antibiotics were not determined, and they may have influenced our results as unmeasured confounding factors in the analysis. Second, the current study was performed in a single center; for this reason, factors such as the rate of referrals or surgery for complex disorders could have impacted the results.

In conclusion, our data showed that *A. baumannii* genospecies is an independent predictor of mortality in patients with ACB complex bacteremia, emphasizing the importance of genotyping for correct species identification and prognosis prediction.
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